Abstract: ［Abstract］ Objective〖HTSS〗〓To explore the etiology of dwarfism and observe the effect of recombinant human growth hormone on growth hormone deficiency(GHD) and idiopathic short stature(ISS).
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓The 485 cases of dwarfism were classified according to the etiology. The prepubertal GHD and ISS children were divided into the recombinant human growth hormone treatment group and the control group, and height, growth rate(GV) and height standard deviation score(HtSDS) were compared before and 3 months after treatment and 6 months after treatment. Bone age was compared before treatment and 6 months after treatment.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓Among the children with dwarfism, ISS had a maximum of 185 cases, followed by GHD 140 cases, and rare disease was found. In the GHD and ISS groups, the height of the treatment group increased gradually, the GV increased first and then decreased, and the HtDSD increased gradually. The changes of height, GV and HtDSD in the control group were not obvious. Height, GV and HtDSD in the treatment group were significantly higher than those in the control group.  There was statistically significant difference in interaction between groups, between time points and between groups(P＜005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓The causes of dwarfism in children were various, and ISS and GHD were more common.The application of recombinant human growth hormone in the early stage of patients with GHD and ISS can achieve catchup growth.

Key words: growth disorders, growth hormone, child